Biaryl imidazole derivatives for regulating CYP17

US9199975B2 · kind B2 · utility

Assignee

• Asana BioSciences, LLC · US

Inventors

• Roger Smith · Madison, US
• Nicholas James Laping · Malvern, US
• Scott K. Thompson · Phoenixville, US
• Raghava Reddy Kethiri · Noida, IN
• Dhanalakshmi Sivanandhan · Noida, IN
• Chandregowda Venkateshappa · Noida, IN
• Bheemashankar A. Kulkarni · Noida, IN
• Purushottam Dewang · Kanchinakote, IN
• Rajendra Kristam · Noida, IN
• Srinivas Rao Kasibhatla · San Diego, US
• Rajesh Devraj · Chesterfield, US

Key dates

• Filing date: Sep 30, 2012
• Grant date: Dec 1, 2015
• Expiry date: Sep 30, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/14
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present application provides novel imidazole compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in inhibiting CYP17 activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with CPY17 activity. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer, such as prostate cancer.